StoryPeople
Allan Reine becomes CEO as Prime Medicine refocuses on liver programs
Prime Medicine announced a strategic restructuring that deprioritized chronic granulomatous disease programs and refocused on in vivo liver therapies for Wilson disease and alpha-1 antitrypsin deficiency. CFO Allan Reine succeeded Keith Gottesdiener as CEO, with workforce reduction and cost cuts to extend runway.
- Allan Reine, M.D. (CFO) became CEO; Keith Gottesdiener stepped down.
- Deprioritized: ex vivo CGD programs; continued: in vivo liver programs (Wilson, AATD).
- Initial clinical data from both liver programs expected in 2027.
- Workforce reduction and cost cuts to focus on liver franchise and partnerships.